Schedule 8 for treatment-resistant depression when prescribed by a psychiatrist authorised under the Authorised Prescriber scheme, or in an approved clinical trial. Schedule 9 for every other use.TGA: accessing MDMA and psilocybine as a psychiatrist
Not on the Australian Register of Therapeutic Goods: an unapproved medicine.
MDMA
Schedule 8 for post-traumatic stress disorder when prescribed by a psychiatrist authorised under the Authorised Prescriber scheme, or in an approved clinical trial. Schedule 9 for every other use.TGA: prescribe MDMA or psilocybine (psychiatrists)
Not on the Australian Register of Therapeutic Goods: an unapproved medicine.
Spravato was registered on 9 March 2021 for treatment-resistant depression and listed on the Pharmaceutical Benefits Scheme on 1 May 2025.
Ketamine
Schedule 8. In October 2023 the TGA decided not to add further controls for use alongside psychotherapy.TGA final decision, October 2023
None recorded here
LSD (lysergide)
Schedule 9: a prohibited substance, available only for approved medical or scientific research.
None recorded here
DMT (N,N-dimethyltryptamine)
Schedule 9. Harmala alkaloids, the other component of ayahuasca, are also in Schedule 9 with narrow exceptions.
None recorded here
Mescaline
Schedule 9.
None recorded here
Psilocin (psilocine)
Schedule 9.
None recorded here
Ibogaine and noribogaine
Schedule 4: prescription-only medicines.
None recorded here
Limits of this page
States and territories add their own rules (for example, Victoria requires notification before each patient is treated). They are not listed here.
Rows without their own link come from the index of the current Poisons Standard.
The table is checked by hand, so it can lag a new instrument. The date above says when it was last checked.
Please note
This page describes the law and public records. It is not medical or legal advice and not an invitation to seek treatment. No MDMA or psilocybin product is on the Australian Register of Therapeutic Goods; only TGA-authorised psychiatrists can prescribe them. Speak to your GP.
Australia's Therapeutic Goods Administration has published interim decisions on proposed amendments to the Poisons Standard from ACMS #48, Joint ACMS-ACCS #42 and ACCS #41, and invited comment by 4 December 2026. The notice covers interim decisions only; the amendments are not final.
The TGA has published its interim decisions on proposed amendments to the Poisons Standard considered at ACMS #47 and Joint ACMS-ACCS #40, and invites comment. The closing date for submissions is 10 July 2026. The notice is a summary only and does not list the substances or amendments covered.
Why it matters: The notice marks the interim stage of scheduling, so anyone with an interest in the proposed Poisons Standard amendments has until 10 July 2026 to comment before a final decision.
The TGA has extended the closing date for comment on its interim decision on a proposed amendment to the Poisons Standard concerning psilocybine, from ACMS #47, to 31 July 2026. The interim decision follows the June 2025 advisory committee meeting.
The TGA has published its notice of final decisions on whether to amend the Poisons Standard, following the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The publication is issued under regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990. The feed supplied only a summary, so the specific substances and outcomes are not stated here.
Why it matters: The notice is the formal record of which scheduling proposals were accepted or rejected, so companies and prescribers can check whether a compound's legal status changed.
The TGA has published interim decisions on proposed amendments to the Poisons Standard arising from the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The notice invites comment, with a closing date of 23 January 2026. The feed gave no further detail on which substances or schedules the interim decisions cover.